Form 4: Mirum Pharmaceuticals CEO Acquires Stock Options and Restricted Stock Units

Mirum Pharmaceuticals CEO, Christopher Peetz, acquired stock options, restricted stock units, and performance restricted stock units on January 21, 2025.

Summary

• Mirum Pharmaceuticals CEO, Christopher Peetz, was granted stock options for 153,550 shares at an exercise price of $47.98 on January 21, 2025.
• These options vest over a period of 4 years, with 1/4 vesting one year after the grant date and the remainder vesting monthly over the following 36 months.
• Peetz also received 38,390 restricted stock units (RSUs) that vest in three equal annual installments starting January 21, 2026.
• Additionally, 75,000 performance-based restricted stock units (PSUs) were granted, with 2/3 vesting on March 15, 2025, and the remaining 1/3 vesting on March 15, 2026.
• The vesting of the PSUs was triggered by the achievement of certain performance criteria.

Sentiment

Score: 7

Explanation: The document reflects standard executive compensation practices, which is generally viewed positively as it aligns management's interests with shareholders. The vesting schedules and performance criteria are also positive indicators.

Positives

• The grant of stock options and restricted stock units aligns the CEO's interests with those of the shareholders.
• The vesting schedules for the options and RSUs encourage long-term commitment from the CEO.
• The achievement of performance criteria for the PSUs suggests positive performance by the company.

Risks

• The value of the stock options is dependent on the future performance of the company's stock price.
• The vesting of the restricted stock units is contingent on the CEO's continued employment with the company.

Industry Context

This type of equity compensation is common for executives in publicly traded companies, aligning their interests with shareholders and incentivizing performance.

Comparison to Industry Standards

• Equity grants are a standard practice for executive compensation in the biotechnology and pharmaceutical industries.
• Companies like BioMarin Pharmaceutical and Vertex Pharmaceuticals also use stock options and restricted stock units as part of their executive compensation packages.
• The vesting schedules and performance criteria are typical for these types of grants, designed to retain talent and incentivize long-term value creation.

Stakeholder Impact

• Shareholders may view the equity grants positively as they align the CEO's interests with the company's long-term success.
• Employees may see this as a sign of the company's commitment to its leadership.

Key Dates

Keywords

stock options, restricted stock units, performance stock units, executive compensation, insider trading, Mirum Pharmaceuticals, MIRM, Christopher Peetz